ClinicalTrials.gg
CompletedNCT00711477Updated Jan 6, 2015Results posted

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

A Phase 2 interventional study of Naltrexone SR 32 mg/bupropion SR 360 mg/day and Placebo in Obesity, sponsored by Orexigen Therapeutics, Inc. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-01-06.

Sponsored by Orexigen Therapeutics, Inc · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Enrollment
14th of 23
46 · median 67
Started
2008
with 2 others
Phase 2
5 of 23
none open now
Registered
8th of 23
by date
Lead sponsor
10 of 23
Orexigen Therapeutics, Inc

Among the 23 studies testing naltrexone in Obesity, this one is the 14th largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 2, and was the 8th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this study was to assess the effect of naltrexone SR/bupropion SR (NB) on brain function in response to food cues using functional magnetic resonance imaging in overweight or obese subjects.

03

Conditions studied

  • Obesity

Keywords

  • obesity
  • overweight
  • magnetic resonance imaging
  • naltrexone
  • bupropion
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right-handed, female subjects, 18 to 45 years of age
  • (BMI) ≥ 27 and ≤ 40 kg/m²
  • Free from illness or disease as determined by medical history and physical examination
  • Able to provide proof of identity during the enrollment process
  • In good general health, without clinically significant medical history, physical examination findings or laboratory results
  • Laboratory values obtained within 30 days of study entry within normal range for healthy volunteers.
  • Normal urinalysis on initial screening day defined as: negative glucose, negative or trace protein, and negative or trace
  • Normotensive (systolic ≤140 mm Hg, diastolic ≤90 mm hg)
  • On no concomitant medications with the exception of oral , vitamins, and over the counter pain, indigestion or allergy medication
  • All women of child bearing potential must be non-lactating, must have a negative STAT pregnancy test, and agree to use effective contraception methods throughout study period and for 30 days after discontinuation of study drug. The following are considered effective methods of contraception: Combination or progestin-only birth control pills (oral contraceptives), vaginal contraceptive rings, contraceptive patches, Depo Provera, intrauterine devices, barrier methods with spermicide (condom/foam, diaphragm/ spermicide), abstinence. (Subjects who have had a tubal ligation, hysterectomy or are for 2 years are considered NOT to be of child bearing potential)
  • For women not using hormonal methods of contraception, should be in the follicular phase of the menstrual cycle at the baseline visit.
  • Non-smoker and no use of tobacco or nicotine products for at least 6 months prior to baseline. On screening and study days, we will test the subjects' urine for presence of nicotinine/cotinine (STAT) test as confirmatory evidence of being a non-smoker in addition to their self-report. A Tobacco Questionnaire and Breath CO will also be administered for eligibility on the day of screening for confirmation purposes.
  • No clinically significant abnormality on , baseline \<470
  • Able to comply with all required study procedures
  • Available for follow up for the duration of the study
  • Willing and able to give written

Exclusion criteria

Exclusion Criteria:

  • Obesity of known endocrine or genetic origin (e.g., untreated hypothyroidism, Cushing's syndrome, Prader Willi Syndrome, established Polycystic Ovary Syndrome)
  • Inability to participate in fMRI scanning sessions
  • History of occupational exposure to metal flakes in their bodies or eyes.
  • History of known indwelling ferromagnetic metals or fragments.
  • History of acute or chronic illness that requires medical therapy including active gastrointestinal conditions that might interfere with drug absorption
  • History or presence of hepatic, renal, cardiovascular or gastrointestinal diseases
  • Type I or Type II diabetes mellitus requiring pharmacotherapy
  • Active or history of malignancy (other than non-melanoma skin cancer or surgically cured cervical cancer) within 5 years of enrollment
  • Serious psychiatric illness, including lifetime history of psychiatric hospitalization, suicide attempt, bipolar disorder, schizophrenia or other psychosis, bulimia, or anorexia nervosa; current serious personality disorder, (e.g. borderline or antisocial), major depressive disorder within the previous two years, suicidal ideation or need for psychiatric treatment in the previous 6 months.
  • In need of medications for the treatment of a psychiatric disorder within the previous 6 months prior to randomization.
  • IDS-SR total score >25 or scores >1 in items 5 (sadness), 6 (irritability), 7 (anxiety/tension) or 18 (suicidality)
  • History of alcohol or drug abuse, current or within 2 years
  • Unable to abstain from caffeinated product consumption for at least 48 hours
  • History of surgical intervention for obesity
  • Use of drugs, herbs, or dietary supplements believed to significantly affect body weight or participation in a weight loss management program within one month prior to randomization.
  • History of to bupropion or naltrexone
  • History of seizure disorder or predisposition to seizures (e.g., history of cerebrovascular accident, brain surgery, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥ 15 minutes, skull fracture, subdural hematoma, or febrile seizures) or need for therapy with anticonvulsant medication.
  • History of treatment with bupropion or naltrexone within 12 months
  • Positive urine drug screen - STAT test performed on each day of study.
  • Pregnant or breast-feeding
  • Planned surgical procedure or trip that can impact the conduct of the study
  • Use of drug, device or procedure within 30 days
  • Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study
  • Participation in any previous clinical trial sponsored by Orexigen Therapeutics.
  • Study personnel, sponsor representatives and their immediate families.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    NB32

    Naltrexone SR 32 mg/bupropion SR 360 mg/day

    Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day · Other: fMRI scan

  • Placebo comparator
    Placebo

    Placebo tablets

    Drug: Placebo · Other: fMRI scan

Interventions

  • DrugNaltrexone SR 32 mg/bupropion SR 360 mg/day

    Drug page: Naltrexone

  • DrugPlacebo
  • OtherfMRI scan

    fMRI to assess the effects of the drug/placebo on areas of the brain

    Also known as: functional magnetic resonance imaging to assess the effects of the drug/placebo on areas of the brain

06

What researchers measure

Primary outcomes

  1. Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal

    Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

    Time frame: Baseline, 4 weeks

  2. Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate

    Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

    Time frame: Baseline, 4 weeks

  3. Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1

    Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

    Time frame: Baseline, 4 weeks

  4. Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2

    Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

    Time frame: Baseline, 4 weeks

  5. Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal

    Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

    Time frame: Baseline, 4 weeks

  6. Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula

    Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

    Time frame: Baseline, 4 weeks

Secondary outcomes

  1. Percent Change in Body Weight

    Time frame: Baseline, 4 weeks

  2. Dutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score

    The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome).

    Time frame: Baseline, 4 weeks

  3. Dutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score

    The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome).

    Time frame: Baseline, 4 weeks

  4. Dutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score

    The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome).

    Time frame: Baseline, 4 weeks

  5. Dutch Eating Behavior Questionnaire - Change in External Eating Subscale Score

    The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome).

    Time frame: Baseline, 4 weeks

  6. Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

    Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

    Time frame: Baseline, 4 weeks

07

Results

Posted Jan 6, 2015

Participant flow

Participant flow — Overall Study
MilestoneNB32Placebo
Started2323
Completed2020
Not completed33
Withdrew: Adverse event31
Withdrew: Lost to follow-up01
Withdrew: Noncompliance01

Outcome measures

PrimaryResponse to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

Time frame:
Baseline, 4 weeks
Reported as:
Mean · percent activation
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal
percent activationPlaceboNB32
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Frontal-0.35 (-0.48 to -0.22)0.34 (0.21 to 0.47)
Statistical analysis
  • Placebo vs NB32 · Mean difference (final values): 0.70 · 90% CI 0.50 to 0.90
SecondaryPercent Change in Body Weight
Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · percentage of body weight
Percent Change in Body Weight
percentage of body weightNB32Placebo
Percent Change in Body Weight-0.99 ± 0.44-0.43 ± 0.44
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.380 · Mean difference (net): -0.56 · 95% CI -1.83 to 0.72Type III sums of squares from ANCOVA model: Treatment and Baseline
SecondaryDutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome).

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · units on a scale
Dutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score
units on a scaleNB32Placebo
Dutch Eating Behavior Questionnaire - Change in Restrained Eating Subscale Score1.47 ± 0.861.87 ± 0.86
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.744 · Mean difference (net): -0.40 · 95% CI -2.87 to 2.07Type III sums of squares from ANCOVA model: Treatment and Baseline
SecondaryDutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome).

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · units on a scale
Dutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score
units on a scaleNB32Placebo
Dutch Eating Behavior Questionnaire - Change in Emotional Eating A Subscale Score-1.16 ± 0.770.48 ± 0.77
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.139 · Mean difference (net): -1.64 · 95% CI -3.84 to 0.56Type III sums of squares from ANCOVA model: Treatment and Baseline
SecondaryDutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome).

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · units on a scale
Dutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score
units on a scaleNB32Placebo
Dutch Eating Behavior Questionnaire - Change in Emotional Eating B Subscale Score-0.90 ± 0.550.45 ± 0.55
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.094 · Mean difference (net): -1.36 · 95% CI -2.96 to 0.24Type III sums of squares from ANCOVA model: Treatment and Baseline
SecondaryDutch Eating Behavior Questionnaire - Change in External Eating Subscale Score

The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome).

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · units on a scale
Dutch Eating Behavior Questionnaire - Change in External Eating Subscale Score
units on a scaleNB32Placebo
Dutch Eating Behavior Questionnaire - Change in External Eating Subscale Score-2.64 ± 1.03-0.16 ± 1.03
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.102 · Mean difference (net): -2.48 · 95% CI -5.48 to 0.51Type III sums of squares from ANCOVA model: Treatment and Baseline
SecondaryChange in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · units on a scale
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire
units on a scaleNB32Placebo
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire-13.55 ± 4.67-4.14 ± 4.41
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.160 · Mean difference (net): -9.40 · 95% CI -22.7 to 3.89Type III sums of squares from ANCOVA model: Treatment and Baseline
PrimaryResponse to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

Time frame:
Baseline, 4 weeks
Reported as:
Mean · percent activation
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate
percent activationPlaceboNB32
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Anterior Cingulate-0.42 (-0.52 to -0.32)0.16 (0.04 to 0.28)
Statistical analysis
  • Placebo vs NB32 · Mean difference (final values): 0.60 · 90% CI 0.40 to 0.80
PrimaryResponse to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

Time frame:
Baseline, 4 weeks
Reported as:
Mean · percent activation
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1
percent activationPlaceboNB32
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 1-0.16 (-0.32 to 0.00)0.60 (0.40 to 0.80)
Statistical analysis
  • Placebo vs NB32 · Median difference (final values): 0.75 · 90% CI 0.50 to 1.00
PrimaryResponse to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

Time frame:
Baseline, 4 weeks
Reported as:
Mean · percent activation
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2
percent activationPlaceboNB32
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Hippocampal Region 2-0.79 (-0.99 to -0.59)0.21 (0.01 to 0.41)
Statistical analysis
  • Placebo vs NB32 · Mean difference (final values): 0.99 · 90% CI 0.74 to 1.24
PrimaryResponse to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

Time frame:
Baseline, 4 weeks
Reported as:
Mean · percent activation
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal
percent activationPlaceboNB32
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Superior Parietal-0.56 (-0.87 to -0.25)0.74 (0.34 to 1.04)
Statistical analysis
  • Placebo vs NB32 · Mean difference (final values): 1.30 · 90% CI 0.95 to 1.65
PrimaryResponse to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula

Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo.

Time frame:
Baseline, 4 weeks
Reported as:
Mean · percent activation
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula
percent activationPlaceboNB32
Response to Food Related Cues Using Functional Magnetic Resonance Imaging - Posterior Insula-0.16 (-0.25 to -0.07)0.30 (0.20 to 0.40)
Statistical analysis
  • Placebo vs NB32 · Mean difference (final values): 0.44 · 90% CI 0.31 to 0.57

Adverse events

Collected over baseline to week 4. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NB32—0/23 (0%)10/23 (43.5%)
Placebo—0/22 (0%)2/22 (9.1%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNB32Placebo
NauseaGastrointestinal disorders5/230/22
VomitingGastrointestinal disorders5/230/22
HeadacheNervous system disorders3/231/22
AnxietyPsychiatric disorders2/230/22
MigraineNervous system disorders0/231/22
ConstipationGastrointestinal disorders1/230/22
DizzinessNervous system disorders1/230/22
DepressionPsychiatric disorders1/230/22
PalpitationsCardiac disorders1/230/22
Feeling abnormalGeneral disorders1/230/22

Baseline characteristics

Randomized subjects

Age, Continuous
Age, Continuous(years)NB32PlaceboTotal
Mean30.96 ± 7.6830.39 ± 8.4630.67 ± 7.99
Sex: Female, Male
Sex: Female, Male(Participants)NB32PlaceboTotal
Female232346
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NB32PlaceboTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American12820
White3811
Other7512
Unknown or Not Reported011
Weight
Weight(kg)NB32PlaceboTotal
Mean87.70 ± 15.8389.59 ± 13.3488.64 ± 14.50
BMI
BMI(kg/m^2)NB32PlaceboTotal
Mean32.96 ± 4.3031.80 ± 3.1032.38 ± 3.75
08

Study locations

1 site
  • Brookhaven National Laboratory Medical Department
    Upton, New York 11973, United States
09

References and documents

Publications

  • Wang GJ, Tomasi D, Volkow ND, Wang R, Telang F, Caparelli EC, Dunayevich E. Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. Int J Obes (Lond). 2014 May;38(5):682-8. doi: 10.1038/ijo.2013.145. Epub 2013 Aug 8. PubMed 23924756 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 4 years 7 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2008
First posted
Jul 9, 2008
Start
Sep 2008
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results delay requested
Oct 23, 2012
Results first posted
Jan 6, 2015
Last update
Jan 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00711477
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Jul 9, 2008
Start date
Sep 2008
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Jan 6, 2015
Last update
Jan 6, 2015

Study contacts

Gene-Jack Wang, MD
principal investigator · Brookhaven National Laboratory

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion